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Abstract: IgG4-related disease (IgG4-RD) is a rare entity consisting
of inflammation and fibrosis that has been described in multiple organs.
Concrete diagnostic criteria have been established recently and there is a
lack of large series of patients.
To describe the clinical presentation, histopathological character-
istics, treatment and evolution of a series of IgG4-RD Spanish patients.
A retrospective multicenter study was performed. Twelve hospitals
across Spain included patients meeting the current 2012 consensus
criteria on IgG4-RD diagnosis.
Fifty-five patients were included in the study, 38 of whom (69.1%)
were male. Median age at diagnosis was 53 years. Thirty (54.5%)
patients were included in the Histologically Highly Suggestive IgG4-
RD group and 25 (45.5%) in the probable IgG4-RD group. Twenty-six
(47.3%) patients had more than 1 organ affected at presentation. The
most frequently affected organs were: retroperitoneum, orbital pseudo-
tumor, pancreas, salivary and lachrymal glands, and maxillary sinuses.
Corticosteroids were the mainstay of treatment (46 patients, 83.6%).
Eighteen patients (32.7%) required additional immunosuppressive
agents. Twenty-four (43.6%) patients achieved a complete responseo´pez-Torres, MD, J ,
Gea, MD, and Gonzalo Salvador-Cervello´, MD
This is the largest IgG4-RD series reported in Europe. Patients were
middle-aged males, with histologically probable IgG4-RD. The
systemic form of the disease was frequent, involving mainly sites of
the head and abdomen. Corticosteroids were an effective first line
treatment, sometimes combined with immunosuppressive agents.
Neither fatalities nor malignancies were attributed to IgG4-RD.
(Medicine 94(32):e1275)
Abbreviations: DMARDs = disease modifying antirheumatic
drugs, GEAS = Group of Autoimmune Diseases, IgG4-RD =
IgG4-related disease, IQR = interquartile range, REEIGG4 =
Spanish Register of IgG4-related disease, SEMI = Spanish Society
of Internal Medicine.
INTRODUCTION
I gG4-related disease (IgG4-RD) is a fibro-inflammatory dis-order that is often characterized by the presence of a pseu-
dotumor(s) with locally expansive behavior. Such patients are
often misdiagnosed initially as having a malignancy. Other
patients present with systemic symptoms including fever,
malaise, and weight loss.1 These different presentations, which
recapitulate only some of the ways in which IgG4-RD can
present, are not mutually exclusive.
IgG4-RD includes many previously recognized conditions
that affected single organs such as Mikulicz’s disease or
Ormond’s disease. Since 2001, when high levels of IgG4 were
described in some patients with autoimmune pancreatitis,2 the
knowledge on this entity has increased dramatically. In the
following years, several authors described series of patients
with multiple organs involved3 and the name ‘‘IgG4-related
sclerosing disease’’ was adopted. The first diagnostic consensus
was established in 2009 by Japanese experts.4 They also
established the current name of the disease: IgG4-RD. Many
case reports and short series, with a myriad of inclusion criteria
can be found in the literature. Approximately three-quarters of
the patients reported in the literature to date were Japanese.5
Because of those methodological biases, it is difficult to extract
solid evidence. In 2012, an international consensus determined
the current IgG4-RD diagnostic criteria,6 based on pathologic
characteristics, leaving IgG4 serum elevation as a complemen-
tary finding. The organ-specific involvement has also been
defined, withdrawing eponyms and old terms.7 The largestpanese multicenter study published in
22 patients, but only 76 of them met the
sensus.8 The only European multicenter
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quartile 75. Comparisons between variables were performedstudy available included 25 patients from a French nationwide
cohort and used the Japanese expert’s criteria.9
In order to apply the new diagnostic criteria and to deepen
in the understanding of the clinical course, treatment and
evolution of IgG4-RD, a Spanish nationwide multicenter reg-
ister was created. Here we report the results of the 55 patients
included.
METHODS
Spanish Register of IgG4-Related Disease
(REEIgG4)
In 2009, we reported the prevalence of IgG4 infiltration
among patients affected with idiopathic retroperitoneal fibrosis
(IRPF), and therefore of IgG4-related retroperitoneal fibrosis.10
In October 2013, after the publication in the previous year of the
new Ig4-RD diagnostic criteria, the need of a nationwide
register in order to unify the management of those patients
emerged. The register was approved and created within the
Spanish Society of Internal Medicine (SEMI) and its Group of
Autoimmune Diseases (GEAS).
Register Management
The respective institutional review boards from the differ-
ent centers approved the study. A standardized form was given
to every contributor. Once filled, the forms were returned and all
personal data from the patients were removed. Each one was
assigned a register number.
Inclusion Criteria
The recruitment period ranged from November 2013 to
November 2014. Patients eligible for the study could be intro-
duced retrospectively or prospectively. The basic inclusion
criteria was to meet the 2012 international diagnostic consensus
on IgG4-RD by Deshpande et al,6 based on pathology findings
and clinical correlation. The technical procedures recom-
mended were the same (IgG4 staining with monoclonal anti-
bodies, preference for surgical biopsies, cell counts at 400
calculating the mean cell counts in at least 3 high power fields or
hpf in 3 different hot spots). Pathologic evaluations were
performed at every center separately. This classification
included 3 categories as described elsewhere. Only patients
with Histologically Highly Suggestive IgG4-RD or Probable
Histological Features of IgG4-RD were included in this study.
Epidemiological Study
The following data were collected: the hospital center at
which the patient was evaluated, sex, birth date, age at diag-
nosis, date of the first and last control and the presence of other
autoimmune conditions.
IgG4-RD Study
The extent of the disease was defined as systemic if there
were 2 or more organs affected. Otherwise it was considered
localized. The specific organs included were those already cited
previously in the literature. IgG4 serum determinations were
made by nephelometry or by enzyme immunoassay, considering
normal values 5 to 135mg/dL.
Ferna´ndez-Codina et alTreatment and Evolution
The use of corticosteroids, with maximum doses, time
under maximum doses, time of dosage decrease, and current
2 | www.md-journal.comdose were noted. Other treatments like radical surgery, immu-
nosuppressive agents, and biologic therapies were also
recorded. Regarding evolution, resolution after treatment was
divided into 3 subsets: complete (complete regression of the
fibrotic mass/masses and systemic symptoms), partial (<50%
of regression of the mass/masses and cease of the systemic
symptoms) and none (no response). During follow-up, the
appearance of malignancies or deaths and the cause of the
decease were reported, as well as previous cancers.
Statistical Analysis
Descriptive statistics included median, quartile 25 and
Medicine  Volume 94, Number 32, August 2015using Chi-square tests. The statistical study was performed with
SPSS (version 18.0; SPSS, Inc., Chicago, IL).
RESULTS
Patients
Fourteen medical centers across Spain sent eligible
patients for the study. Sixty-four cases were referred for evalu-
ation but only 55 were included. All 9 patients who did not meet
the inclusion criteria had almost 2 IgG4-RD pathologic criteria
but the immunohistochemical study including IgG4 cell count
and/or IgG4þ/IgGþ ratio was not available.
Regarding the patients included in the study, 38 (69.1%)
were male, with an approximate male to female ratio 3:1. The
median age at diagnosis was 53 years (interquartile range [IQR]
41–64). The diagnosis of previous autoimmune diseases was
reported in 9 (16.4%) patients: 5 (5.7%) had been diagnosed of
Hashimoto’s thyroiditis, and 4 of rheumatoid arthritis, antineu-
trophil cytoplasmic antibodies-negative systemic vasculitis,
ankylosing spondylitis and Graves’ disease, once (1.8%) each.
Pathology and Distribution of Involvement by
Organs
Samples of biopsies of IgG4-RD patients are exposed in
Figure 1. Fifty patients (90.9%) had surgical biopsy specimens
and 5 (9.1%) had needle aspiration samples. Thirty patients
(54.5%) were included in the Histologically Highly Suggestive
IgG4-RD histological group and 25 (45.5%) in the Probable
Histological Features of IgG4-RD group. The histopathological
characteristics and serum IgG4 levels are summarized in
Table 1. Twenty-six patients (47.3%) had systemic IgG4-RD
with more than 1 organ affected at presentation. The different
tissues involved and the frequencies are described in Figure 2.
There were no statistically significant differences between
systemic and localized IgG4-RD regarding organ involvement,
except for maxillary sinus involvement, more associated to the
systemic form (P¼ 0.001).
Treatment
Forty-seven patients (85.5%) received corticosteroids.
The median maximum dose was 55mg/day (IQR 30–60) during
1 month (IQR 0.75–1.5). Corticosteroid tapering lasted a
median of 8 months (IQR 4–11.25). Twelve patients
(21.12%) were maintained on a mean dose prednisone of
7.5mg/day (IQR 5–10).
Nineteen patients (34.5%) received immunosuppressive
agents due to corticosteroid resistance (sustained disease
activity, progression of clinical symptoms or flares when down-
scaling steroids) or secondary effects. Mofetil mycophenolate/
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Microscopic samples of IgG4-related disease. Panel A shows immunostaining for IgG4-positive plasma cell infiltrate in a
hop
son
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azathioprine in 9 (16.4%), azathioprine followed by methotrex-
ate in 2 (3.6%), and azathioprine followed by cyclophospha-
mide in 2 patients each (2.9%). Three subjects (5.5%) received
biologic treatment with rituximab. Finally, 16 individuals
(29.1%) underwent radical surgery in the context of the diag-
nostic process and/or local compression. They were all per-
formed before the IgG4-RD diagnosis was made.
In summary, 35 (63.6%) patients received medical treat-
ment only, 4 (7.3%) underwent surgery alone, and 12 (21.8%)
received a combination of medical and surgical interventions. In
addition, 4 (7.3%) patients did not receive any treatment. One
because she was asymptomatic, and the other 3 because they
were diagnosed just near the inclusion period ending, and no
therapeutic decision had been made at that moment. Patients
with systemic IgG4-RD were more likely to receive immuno-
suppressive agents than those with localized disease
(P¼ 0.004).
Evolution and Survival
The median follow-up was 23.03 months (IQR 8.08–
55.06). Calculations were made with 52 patients at risk.
Twenty-four individuals (46.2%) presented a complete
response and 26 (50%) presented a partial response. One patient
(1.9%) did not respond to the treatment and in another, the
lesion was too small to evaluate the response. Within the 19
subjects who only took prednisone, 10 had a complete resol-
ution and 14 were able to discontinue the medication. The
comparison between systemic IgG4-RD and localized IgG4-
RD, discarding the 2 nonresponders, showed that localized
retroperitoneal mass, at 400. Panel B illustrates an important lymp
hematoxylin and eosin at 200. Finally, Panel C, stained with Mas
pleura.IgG4-RD significantly presented more complete responses than
the first group (8 vs. 16, P¼ 0.24). Twenty subjects (38.5%)
presented recurrences. Systemic forms of IgG4-RD had a
TABLE 1. Histopathological Characteristics and Serum IgG4 Leve
Highly Suggest
Lymphoplasmacytic infiltrate 100% (30)
Storiform fibrosis 93.3% (28)
Obliterative phlebitis 43.3% (13)
Median IgG4 cells

56 (Q1 43.2
Median IgG4/IgG ratio

126.7 (Q1 80.2
Median serum IgG4mg/dLy 223 (Q1 123.
IgG4-RD¼ IgG4-related disease.
Per high power field at 400.
yThirty-eight serums available; serum IgG4 normal range 5 to 145mg/d
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.statistically significant tendency to flare when compared with
localized IgG4-RD forms (15 cases vs. 5 cases, P¼ 0.00).
During the follow-up, 2 fatalities were reported (3.6%), 1
due to a car accident and another due to a sepsis secondary to an
episode of pneumonia. No deaths were directly attributed to
IgG4-RD. Appearance of malignancy or premalignant con-
ditions were reported in 5 occasions, corresponding to 4
patients. The following conditions were reported: monoclonal
gammopathy of unknown significance in twice, prostate cancer
once, breast cancer once and 1 patient developed a cervix cancer
previously to IgG4-RD.
DISCUSSION
We have presented a multicenter observational study
including 55 Spanish patients with IgG4-RD. It is the first
non-Japanese study using the current IgG4-RD diagnostic
criteria, and the largest European series by the moment. Also,
the fact that it comes from a single country adds homogeneity to
the population and accuracy to the data recruitment. There was a
male predominance, typical of what has been reported by other
investigators. Middle-aged individuals were the most affected.
The disease tended to affect multiple organs and it had an
acceptable response to treatment with corticosteroids, immu-
nosuppressive agents and biologics. Flares and incomplete
response to the treatment were associated to the systemic form
of IgG4-RD. No deaths were directly related with the disease
and the malignancy rate was low.
There is limited data in the literature in order to compare
our findings with other studies. We chose the 2 widest series
published in the literature to do so, but limitations emerged
lasmacytic infiltrate in a retroperitoneal mass sample, stainedwith
’s trichrome, depicts the storiform fibrosis at 100 in a sample ofrapidly. On one hand, the French National Society of Interna
Medicine’s register,9 involving 25 patients. This study
described in 2012 a cohort of patients in the vicinity of ou
ls of Spanish Patients With IgG4-Related Disease
ive IgG4-RD Probable IgG4-RD
100% (25)
100% (25)
48% (12)
, Q3 99.3) 26.4 (Q1 10.25, Q3 38.8
, Q3 180.5) 77.4 (Q1 22.2, Q3 350)
5, Q3 1145.2) 93 (Q1 30.8, Q3 494.7
L.
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FIGURE 2. Distribution by organs involved in IgG4-related disease
Spanish patients. Total recount by organs: retroperitoneum 15;
orbitary pseudotumor 12; pancreas and salivary glands 9; maxil-
lary and lachrymal glands 8; aorta and lung, kidney andmesentery
Ferna´ndez-Codina et alcountry. The main bias as a comparator was the use of com-
prehensive diagnostic criteria, what left patients outside the
study. Otherwise, regional differences in the incidence and
presentation of autoimmune pancreatitis type I,11 the corner-
stone from which studies on IgG4-RD started, may be a strong
point of this paper. On the other hand, we chose the SMART8
database, a Japanese study, recently published, including 122
patients. This work included 76 patients fulfilling the 2012
international consensus,6 mixed with 66 patients diagnosed with
the older comprehensive diagnostic criteria.12 This issue con-
stitutes another bias because the reliance of these criteria on
IgG4 serum levels and the difficulty to make comparisons with
mixed cohorts. The role of increased serum IgG4 levels in
diagnosis has been heavily questioned.13,14
The 3 reports agree that the age of presentation is between
60 and 53 years. There are differences between the sex ratio,
where the Asian cohort showed a 1:1 ratio, while the French
cohort showed a male predominance (2.6:1), as well as ours
(3:1). A systematic review of the literature5 including 3366
cases, but with different sets of IgG4-RD diagnostic classifi-
cations, also suggested a trend toward increased male to female
ratios, matching with our results. We found 9 patients over 55
with diverse associated inflammatory diseases. No rheumato-
logic condition has been solidly associated with the presence of
IgG4-RD. Similarly, 4 patients over 25 in the French study also
presented other immune disorders.
The pathological examination showed that all the subjects
had almost 2 of the classical histological features. All patient
reports included the IgG4 cell count and/or the IgG4/IgG ratio.
Probably, in the next years, with the validation and introduction
of new biomarkers like serum plasmablast determinations,15
diagnostic criteria will adapt more to the everyday clinicians
reality with its material limitations.
Regarding the current international classification, nearby
one-half of the patients presented Histologically Highly Sug-
4; gallbladder 3; pachymeninges, pleura and biliary ducts 2;
thyroid, extraocular muscles, breast, pericardium, adenopathic
and mediastinum 1; hypophysis, prostate, liver, skin, and arteries 0.gestive IgG4-RD, while the rest presented Probable Histologi-
cal Features of IgG4-RD. Patients with incomplete histological
features (ie, disclosing fibrotic changes only) were excluded in
4 | www.md-journal.comorder to grant more cohesion. Twenty-six patients, nearby the
half of our sample, had IgG4-RD with more than 1 organ
affected at presentation. These data were close to the 61.4%
of patients with organ involvement different from dacryoade-
nitis and/or sialadenitis reported by the SMART authors. The
French group reported 22 over 25 patients with more than 1
organ involved.We think that a figure between the 2 first studies
may be the right estimation due to the larger size of both
samples. If we review the most frequently affected organs,
all patients in the Japanese study had IgG4-related dacryoade-
nitis or sialadenitis because it was the main inclusion criteria.
Among those patients, retroperitoneal fibrosis (20%) and type I
autoimmune pancreatitis (15.7%) were the following in fre-
quency order. Meanwhile, in the French report the most com-
mon tissues involved were lymph nodes (76%), pancreas (52%)
salivary glands and kidney (44%), biliary duct and retroper-
itoneum (32%). Getting back to our results, retroperitoneum
was the most commonly altered organ, probably overrepre-
sented because the main recruiting center had conducted
previous investigations on IRPF. Twenty-eight over 55 cases,
representing more than the half of our sample, presented almost
one infiltrated tissue located in the head (lachrymal and salivary
glands, orbitary pseudotumor, extraocular muscles, maxillary
sinuses, and pachymeninges). This numbers are comparable to
the other European study. Likewise, a compilation of the cases
reported in the literature with unselected IgG4 organ involve-
ment also showed lachrymal and salivary glands involved in
40% and 29% of the cases, respectively.5 The tropism of IgG4-
RD for the head is currently unexplained. Active search for new
lesions in this area must be conducted by clinicians at diagnosis
and during follow-up because of the systemic nature of IgG4-
RD.
In the field of the therapeutic management, although
patients did not follow any defined treatment scheme, unlike
in the SMART study, results were similar. In the same way,
French cohort treatments were alike. Corticosteroids were the
most commonly prescribed drug. All prescriptions are based on
autoimmune pancreatitis experiences.16 There seems to be
consensus on maintaining high doses of steroids for nearby a
month. The differences appear in the long-term steroid treat-
ment: complete withdrawal or maintenance dose? Most of the
SMART patients received a maintenance dose, with a mean
dose of 4.8mg/day of prednisolone to control the disease. The
French cohort reported a complete withdrawal rate of 30%.
Only the 20% of our patients were put on a long-term low
steroid maintenance regime. The use of rituximab was anec-
dotic in the 3 series (9 patients in total) but with positive results.
In our study, surgical treatment accounted for nearly 30% of the
patients. The initial management by other specialists, diagnostic
aggressiveness and treatment of complications may justify the
use of this procedure.
Immunosuppressive agents were more used in both Euro-
pean series (48% in the French and 32.7% in ours), opposite to
the Japanese series (9%). Disease modifying antirheumatic
drugs (DMARDs) have been reported to be useful in a few
patients with IgG4-RD17 and in similar conditions like in
IRPF18,19 or in autoimmune pancreatitis.20 In our experience,
DMARDs seem an effective treatment, although directed trials
are needed to strengthen this limited evidence. Otherwise, they
may be an option instead of rituximab. Rituximab has been
described as a highly effective treatment in IgG4-RD combined
Medicine  Volume 94, Number 32, August 2015or not with steroids in a study including 10 patients.21 Experi-
ence is still short but B-cell depletion seems the cornerstone of
future therapeutic strategies against IgG4-RD. Our 3 patients
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
treated with rituximab had systemic involvement, with 2 or
more target tissues affected. All of them had damaged tissues
located in the head (maxillary, lachrymal and salivary glands,
orbitary pseudotumor, and pachymeninges) and only 1 had
pleural involvement. In 2 patients, 2 courses of rituximab
1000mg were administered separated by 14 days. The third
one received 375mg/m2/week for 4 weeks. One of the patients
had just received the first dose when this proof was sent while
the other 2 patients did not relapse during follow-up.
There is no outcome measurement tool validated for IgG4-
RD at the moment, but a prototype of activity index was proposed
in 2012.22 This item will be basic for any future trials. Different
composite scores including symptoms, clinical and radiological
itemswere used to define the outcomes of the 3 compared cohorts.
In the Japanese cohort, therewas an 11.5% annual relapse rate and
symptoms were controlled initially in all patients. Half of the
patients relapsed after 7 years. Our total rate of relapses was
38.5%. Patients with systemic IgG4-Rd received more DMARDs,
responded worse and relapsed more than the ones with localized
IgG4-RD. Patients with systemic IgG4-RD should be strictly
monitored and treated more aggressively. Symptom control
was almost a constant, but 47.3% of the patients kept with a
residual inactive fibrotic mass. The available treatments still have
limitations in order to eradicate all the remains of the disease,
especially in the cases with a long period of evolution and more
fibrosis.Mortality was anecdotic, and not linked to IgG4-RD,with
only a dead patient in the French cohort and another 2 in ours (the
SMART study did not mention mortality).
The link between IgG4-RD and neoplasm is still contro-
versial.23 We found that only 7.2% of the patients developed
cancer (solid or hematological) or premalignant conditions after
IgG4-RD diagnosis, all of them with a low level of aggressive-
ness, what matches with the SMART group results (7.4%).
The retrospective character of this study is a clear limita-
tion for the interpretation of the data. Also, conclusions about
treatment regimes and evolution should be taken in consider-
ation but the design of the study was not directed to elucidate
this questions. We expect to give a depiction of IgG4-RD in our
environment with the strength of the latest diagnostic criteria
and the participation of multiple centers.
In conclusion, we described a series of patients with IgG4-
RD in Spain. The disease had preference for head structures,
retroperitoneum and pancreas. There was a good response to
treatment but systemic IgG4-RD is more difficult to treat and
more relapsing. Rituximab introduction may start a new treat-
ment era. Malignancy and mortality were infrequent. Inter-
national collaborative studies and randomized clinical trials
could help clarifying these areas of uncertainty.
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